Structure Therapeutics
This role is responsible for characterizing the preclinical ADME/PK aspects of specific programs, including the selection and supervision of CROs and providing PK, in vitro/in vivo drug metabolism, and PK/PD modeling support. The position involves developing DMPK strategies, overseeing study design and execution, and contributing to regulatory documents such as IND or NDA submissions. Additionally, the role supports clinical pharmacology trial design through DDI risk analysis and provides input for lead identification and clinical dose optimization.
Headquarters
South San Francisco, California, United States
Company Size
51-200 employees
Founded
2017
Structure Therapeutics is a biopharmaceutical company with the mission 'Medicine is our platform. Accessibility is our cure.' The company is focused on developing medicines with an emphasis on accessibility, and maintains an active pipeline and team as indicated on its website.
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Structure Therapeutics.
Structure Therapeutics didn’t post a salary, so this is our estimate from similar listings.
27% below the average for this role